Decitabine ‘better-tolerated alternative’ to chemotherapy for older, fit patients with AML

Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates comparable to those treated with induction chemotherapy but with fewer toxicities, according to results of a randomized phase 3 study.
“Ten-day decitabine provides a better-tolerated alternative to aggressive chemotherapy in older, fit patients with AML,” Michael Lübbert, MD, of the division of hematology, oncology and stem cell transplantation at University of Freiburg Medical Center in Germany, said during a press briefing at European Hematology Association 2022 Hybrid

Older, fit patients with acute myeloid leukemia who received decitabine had transplant and survival rates comparable to those treated with induction chemotherapy but with fewer toxicities, according to results of a randomized phase 3 study.
“Ten-day decitabine provides a better-tolerated alternative to aggressive chemotherapy in older, fit patients with AML,” Michael Lübbert, MD, of the division of hematology, oncology and stem cell transplantation at University of Freiburg Medical Center in Germany, said during a press briefing at European Hematology Association 2022 Hybrid